Cargando…

Value of Different Comorbidity Indices for Predicting Outcome in Patients with Acute Myeloid Leukemia

Age is a dominant predictor of outcome in acute myeloid leukemia (AML). However, it is not clear to which extent comorbidities contribute to this effect. The objective of this study was to determine the impact of pretreatment comorbidities on survival of AML patients. In a single-center retrospectiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wass, Maxi, Hitz, Friederike, Schaffrath, Judith, Müller-Tidow, Carsten, Müller, Lutz P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5061362/ https://www.ncbi.nlm.nih.gov/pubmed/27732646 http://dx.doi.org/10.1371/journal.pone.0164587

Ejemplares similares

Correlation of nutrition-associated parameters with non-relapse mortality in allogeneic hematopoietic stem cell transplantation
por: Schaffrath, Judith, et al.
Publicado: (2021)

Efficacy of targeted drugs in germ cell cancer cell lines with differential cisplatin sensitivity
por: Schaffrath, Judith, et al.
Publicado: (2017)

Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML)
por: Hofmann, Susanne, et al.
Publicado: (2019)

Integrated RNAi screening identifies the NEDDylation pathway as a synergistic partner of azacytidine in acute myeloid leukemia
por: Klosner, Justine, et al.
Publicado: (2021)

DNA-methylation in C1R is a prognostic biomarker for acute myeloid leukemia
por: Božić, Tanja, et al.
Publicado: (2015)

Pre-Transplant Serum Leptin Levels and Relapse of Acute Myeloid Leukemia after Allogeneic Transplantation
por: Schwarzbich, Mark-Alexander, et al.
Publicado: (2022)

P470: SINGLE-CELL METABOLIC MULTIOMICS TO IDENTIFY VULNERABILITIES IN ACUTE MYELOID LEUKEMIA STEM CELLS
por: Antes, Magdalena, et al.
Publicado: (2023)

PB1790: LOOKING ‘BENEATH’ THE SURFACE: PROTEOMICS AND GLYCIPROTEOMICS REVEAL NOVEL TARGETS FOR CAR-T CELL THERAPIES IN ACUTE MYELOID LEUKEMIA (AML)
por: Brysting, Josephine, et al.
Publicado: (2023)

Large case-control study indicates no association of KIR genotype and risk of developing acute myeloid leukemia
por: Heidenreich, Falk, et al.
Publicado: (2023)

P438: INTRACELLULAR CITRATE LEVELS MODULATE ANTI-APOPTOTIC PROTEINS TO ENHANCE VENETOCLAX SENSITIVITY IN ACUTE MYELOID LEUKEMIA STEM CELLS
por: Demir, Aykut, et al.
Publicado: (2023)

Impaired Overall Survival in Young Patients With Acute Myeloid Leukemia and Variants in Genes Predisposing for Myeloid Malignancies
por: Kirschner, Martin, et al.
Publicado: (2022)

MicroRNA-143 targets ERK5 in granulopoiesis and predicts outcome of patients with acute myeloid leukemia
por: Hartmann, Jens-Uwe, et al.
Publicado: (2018)

Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group
por: Lengfelder, Eva, et al.
Publicado: (2012)

miR-451a abrogates treatment resistance in FLT3-ITD-positive acute myeloid leukemia
por: Krakowsky, Rosanna H. E., et al.
Publicado: (2018)

ABR, a novel inducer of transcription factor C/EBPα, contributes to myeloid differentiation and is a favorable prognostic factor in acute myeloid leukemia
por: Namasu, Carolina Yaeko, et al.
Publicado: (2017)

The limited contribution of DNA methylation to PML-RARα induced leukemia
por: Rohde, Christian, et al.
Publicado: (2013)

Correction: Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk Prediction
por: Pohlen, Michele, et al.
Publicado: (2018)

Feasibility of Azacitidine Added to Standard Chemotherapy in Older Patients with Acute Myeloid Leukemia — A Randomised SAL Pilot Study
por: Krug, Utz, et al.
Publicado: (2012)

Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk Prediction
por: Pohlen, Michele, et al.
Publicado: (2016)

CDK7/12/13 inhibition targets an oscillating leukemia stem cell network and synergizes with venetoclax in acute myeloid leukemia
por: He, Lixiazi, et al.
Publicado: (2022)

Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma
por: Stemler, Jannik, et al.
Publicado: (2020)

Identification of the Adapter Molecule MTSS1 as a Potential Oncogene-Specific Tumor Suppressor in Acute Myeloid Leukemia
por: Schemionek, Mirle, et al.
Publicado: (2015)

P408: COMBINATORIAL BCL-2 FAMILY EXPRESSION IN ACUTE MYELOID LEUKEMIA STEM CELLS PREDICTS CLINICAL RESPONSE TO AZACITIDINE/VENETOCLAX
por: Renders, Simon, et al.
Publicado: (2023)

Predictive value of integrin α7 for acute myeloid leukemia risk and its correlation with prognosis in acute myeloid leukemia patients
por: Zeng, Mingyue, et al.
Publicado: (2019)

S123: ACUTE MYELOID LEUKEMIA STEM CELL SUBTYPES DEFINED BY MUTATIONS AND DIFFERENTIATION STATE REGULATE APOPTOTIC DEPENDENCY AND CLINICAL RESPONSE TO VENETOCLAX.
por: Waclawiczek, Alexander, et al.
Publicado: (2023)

Reduced proliferation of bone marrow MSC after allogeneic stem cell transplantation is associated with clinical outcome
por: Katzerke, Christiane, et al.
Publicado: (2023)

A Dynamic rRNA Ribomethylome Drives Stemness in Acute Myeloid Leukemia
por: Zhou, Fengbiao, et al.
Publicado: (2023)

Derepression of retroelements in acute myeloid leukemia with 3q aberrations
por: Mika, Jagoda, et al.
Publicado: (2021)

Clinical value of new drugs in acute myeloid leukemia
por: Ossenkoppele, Gert
Publicado: (2019)

Chronic active Epstein-Barr virus infection of T-cell type, systemic form in an African migrant: case report and review of the literature on diagnostics standards and therapeutic options
por: Wass, Maxi, et al.
Publicado: (2018)

Inhibition of IRE1α-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia
por: Sun, Haibo, et al.
Publicado: (2016)

Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learning
por: Eckardt, Jan-Niklas, et al.
Publicado: (2022)

Expression of protein-tyrosine phosphatases in Acute Myeloid Leukemia cells: FLT3 ITD sustains high levels of DUSP6 expression
por: Arora, Deepika, et al.
Publicado: (2012)

Correction: Inhibition of IRE1α-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia
por: Sun, Haibo, et al.
Publicado: (2017)

Optimizing Treatment Options for Newly Diagnosed Acute Myeloid Leukemia in Older Patients with Comorbidities
por: Oshikawa, Gaku, et al.
Publicado: (2023)

Lysosomes in acute myeloid leukemia: potential therapeutic targets?
por: Rafiq, Sreoshee, et al.
Publicado: (2021)

Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations
por: Eckardt, Jan-Niklas, et al.
Publicado: (2022)

Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax
por: Waclawiczek, Alexander, et al.
Publicado: (2023)

The Prognostic Value and Function of HOXB5 in Acute Myeloid Leukemia
por: Chen, Miao, et al.
Publicado: (2021)

The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia
por: Santini, Valeria, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6oq8oieepp58hhdgbdoqkta5l9